Alternative-C Chemotherapy-free combination of Copanlisib with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and High Tumor Burden (Aktiv)
GABe 2016 FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA IN PATIENTS NOT ELIGIBLE FOR STANDARD IMMUNOCHEMOTHERAPY (Aktiv)
LBL 2018 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (Aktiv)
Zweitlinie oder später
AMG 562 20170533 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (Aktiv)
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
ME-401-003 - TIDAL Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (Aktiv)